

Sheet 1 of 8

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50206/012002
	Serial No.	10/698,572
	Applicant	Barker et al.
	Filing Date	October 31, 2003
	Group	1645
	IDS Filed	January 3, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Issue/Publication/ Filing Date	Patentee or Applicant
	5,541,210	Jul. 30, 1996	Cupps et al.
	6,288,118	Sep. 11, 2001	Nieman et al.
	6,525,018	Feb. 25, 2003	Podolsky
	6,685,917	Feb. 3, 2004	Rosenthal et al.
	6,984,628	Jan. 10, 2006	Bakhit et al.
	2003-0077696	Apr. 24, 2003	Thim et al.
	2003-0078205	Apr. 24, 2003	Podolsky
	2003-0105016	Jun. 5, 2003	Podolsky
	2003-0114384	Jun. 19, 2003	Podolsky
	2003-0134797	Jul. 17, 2003	Podolsky
	2003-0148949	Aug. 7, 2003	Podolsky
	2003-0166535	Sep. 4, 2003	Podolsky
	2003-0181383	Sep. 25, 2003	Podolsky
	2003-0181384	Sep. 25, 2003	Podolsky
	2003-0185838	Oct. 2, 2003	Podolsky
	2003-0185839	Oct. 2, 2003	Podolsky
	2003-0186880	Oct. 2, 2003	Podolsky
	2003-0186882	Oct. 2, 2003	Podolsky
	2003-0186886	Oct. 2, 2003	Podolsky
	2003-0225250	Dec. 4, 2003	Podolsky
	2004-0171544	Sep. 2, 2004	Barker et al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50206/012002
	Serial No.	10/698,572
	Applicant	Barker et al.
	Filing Date	October 31, 2003
	Group	1645
	IDS Filed	January 3, 2008

U.S. PATENT DOCUMENTS			
	2005-0287640	Dec. 29, 2005	Thim et al.
	2006-0019881	Jan. 26, 2006	Thim et al.
	2006-0046958	Mar. 2, 2006	Bakhit et al.
	2006-0111278	May 25, 2006	Thim et al.
	2006-0188471	Aug. 24, 2006	Podolsky
	2006-0189526	Aug. 24, 2006	Podolsky
	2006-0211605	Sep. 21, 2006	Thim et al.
	2006-0241037	Oct. 26, 2006	Olejnik et al.
	2006-0293221	Dec. 28, 2006	Thim et al.
	2007-0148733	Jul. 25, 2006	Woon et al.
	2007-0062517	May 15, 2006	Barker
	U.S.S.N. 10/362,310	Feb. 19, 2003	Podolsky
	U.S.S.N. 10/457,157	Jun. 9, 2003	Podolsky
	U.S.S.N. 11/821,367	Jun. 21, 2007	Podolsky

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	EP 0 534 310	Mar. 31, 1993	EPO	Yes (abstract only)
	WO 86/02271	Apr. 24, 1986	WIPO	
	WO 2005/009459 A1	Feb. 3, 2005	WIPO	
	WO 2005/039619 A1	May 6, 2005	WIPO	
	WO 2005/039640 A1	May 6, 2005	WIPO	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50206/012002
	Serial No.	10/698,572
	Applicant	Barker et al.
	Filing Date	October 31, 2003
	Group	1645
	IDS Filed	January 3, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Bare et al., "Effect of cysteine substitutions on the mitogenic activity and stability of recombinant human keratinocyte growth factor," <i>Biochem. Biophys. Res. Commun.</i> 205:872-879 (1994).
	BLAST alignment of human and rat ITF, currently known as trefoil factor 3 (TTF3).
	Bork, "Powers and pitfalls in sequence analysis: the 70% hurdle," <i>Genome Res.</i> 10:398-400 (2000).
	Bork and Bairoch, "Go hunting in sequence databases but watch out for the traps," <i>Trends Genet.</i> 12:425-427 (1996).
	Brenner, "Errors in genome annotation," <i>Trends Genet.</i> 15:132-133 (1999).
	Communication and Search Results from European Patent Office, mailed May 16, 2006 (EP 97921148.9).
	Cuzzocrea et al., "Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats," <i>Eur. J. Pharmacol.</i> 431:91-102 (2001).
	David et al., "Corneal wound healing modulation using basic fibroblast growth factor after excimer laser photorefractive keratectomy," <i>Cornea</i> 14:227-234 (1995).
	Doerks et al., "Protein annotation: detective work for function prediction," <i>Trends Genet.</i> 14:248-250 (1998).
	Dorland's Medical Dictionary; definition of mucositis.
	Fleiszig et al., "Relationship between cytotoxicity and corneal epithelial cell invasion by clinical isolates of <i>Pseudomonas aeruginosa</i> ," <i>Infect. Immun.</i> 64:2288-2294 (1996).
	Göke et al., "Trefoil peptides promote restitution of wounded corneal epithelial cells," <i>Exp. Cell Res.</i> 264:337-344 (2001).
	Hammer, "Was gibt es neues in der diagnostik und therapie des morbus Crohn und der colitis ulcerosa," <i>Schweiz. Med. Wochenschr.</i> 124:452-460 (1994), abstract in English.
	Harlow and Lane, "Antibodies: a laboratory manual," <i>Cold Spring Harbor Press Inc.</i> , 72-73 (1988).
	Harlow and Lane, "Antibodies: a laboratory manual," <i>Cold Spring Harbor Press Inc.</i> , pg. 76 (1988).
	Harmer et al., "The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity," <i>Biochemistry</i> 43:629-640 (2004).
	Hauser et al., "xP2, a New Member of the P-Domain Family of Potential Growth Factor Members, is Synthesized in <i>Xenopus laevis</i> Skin," <i>J. Biol. Chem.</i> 267(20):14451-14455 (1992).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50206/012002
	Serial No.	10/698,572
	Applicant	Barker et al.
	Filing Date	October 31, 2003
	Group	1645
	IDS Filed	January 3, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	http://www.allaboutvision.com/conditions/cataracts.htm
	http://www.allaboutvision.com/conditions/diabetic.htm
	http://www.allaboutvision.com/conditions/dryeye.htm
	http://www.allaboutvision.com/conditions/glaucoma.htm
	http://www.allaboutvision.com/conditions/hyperopia.htm
	http://www.allaboutvision.com/conditions/amd.htm
	http://www.medterms.com ; definition of mucositis
	http://www.medterms.com ; definition of gastrointestinal tract
	http://cancerweb.ncl.ac.uk ; definition of gastrointestinal tract
	http://cancerweb.ncl.ac.uk ; definition of trefoil
	http://www.thedoctorsdoctor.com ; definition and description of gastrointestinal system
	http://www.hon.ch ; definition of gastrointestinal system
	http://www.mic.ki.se/Diseases/C11.html
	International Search Report, mailed August 31, 2006 (PCT/US03/34796).
	Jaglia et al., "Localization of TFF3 peptide to porcine conjunctival goblet cells," <i>Cell Tissue Res.</i> 296:525-530 (1999).
	Kalin and Bjorkholm, "Prophylactic and empirical treatment of mycoses in neutropenic fever," <i>Lakartidningen</i> 98(16):1899-1903 (2001), abstract only.
	Khan-Lim et al., "Trefoil factors in normal and dry eyes," <i>Trefoils & Mucins 2002</i> , Keble College, Oxford, U.K., April 2-4, 2002 (abstract).
	Life Sciences Dictionary; definition of lesion.
	Medical Encyclopedia: Uveitis from http://www.nlm.nih.gov/medlineplus/print/ency/article/001005.htm
	Moss and Wright, "Molecular aspects of mucosal repair: a summary," <i>Yale J. Biol. Med.</i> 69:155-158 (1996).
	MSN Encarta Dictionary; definition of trefoil

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50206/012002
	Serial No.	10/698,572
	Applicant	Barker et al.
	Filing Date	October 31, 2003
	Group	1645
	IDS Filed	January 3, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	MSN Encarta Dictionary; definitions of homologous and homologue
	Murali et al., "Effect of topically administered platelet-derived growth factor on corneal wound strength," <i>Curr. Eye Res.</i> 13:857-862 (1994).
	National Cancer Institute: Dictionary of Cancer Terms; definition of lesion.
	On-Line Medical Dictionary; definition of cervix uteri
	On-Line Medical Dictionary; definition of mucositis
	Paulsen et al., "Distribution of TFF-peptides and mucins in human nasolacrimal ducts," <i>Trefoils & Mucins 2002</i> , Keble College, Oxford, U.K., April 2-4, 2002 (abstract).
	Paulsen et al., "Distribution of mucins in human pterygia," <i>Trefoils & Mucins 2002</i> , Keble College, Oxford, U.K., April 2-4, 2002 (abstract).
	Pharyngula; http://pharyngula.org/index/weblog/comments/evolution_of_the_mammalian_vagina
	Poulsen et al., "Luminal and parental TFF2 and TFF3 dimer and monomer in two models of experimental colitis in the rat," <i>Regulatory Peptides</i> 126:163-171 (2005).
	Richter et al., "Contribution of the transforming growth factor α B-loop β -sheet to binding and activation of the epidermal growth factor receptor," <i>J. Biol. Chem.</i> 270:1612-1616 (1995).
	Skolnick and Fetrow, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends Biotechnol.</i> 18:34-39 (2000).
	Smith et al., "Production of human beta interferon in insect cells infected with a baculovirus expression vector," <i>Mol. Cell. Biol.</i> 3:2156-2165 (1983).
	Smith and Zhang, "The challenges of genome sequence annotation or 'The devil is in the details,'" <i>Nat. Biotechnol.</i> 15:1222-1223 (1997).
	Tebbutt et al., "Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice," <i>Nat. Med.</i> 8:1089-1097 (2002).
	Tomasetto et al., "hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma," <i>EMBO J.</i> 9:407-414 (1990).
	Wang et al., "Effect of antibody against integrin $\alpha 4$ on bleomycin-induced pulmonary fibrosis in mice," <i>Biochem. Pharmacol.</i> 60:1949-1958 (2000).
	Websters Dictionary – definition trefoil

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50206/012002
		Serial No.	10/698,572
		Applicant	Barker et al.
		Filing Date	October 31, 2003
		Group	1645
		IDS Filed	January 3, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Office Action for U.S. Application No. 10/434,752 (mailed Oct. 1, 2004).
	Office Action for U.S. Application No. 10/434,752 (mailed Feb. 15, 2006).
	Office Action for U.S. Application No. 10/434,752 (mailed Jun. 1, 2007).
	Office Action for U.S. Application No. 10/266,069 (mailed Feb. 27, 2007).
	Office Action for U.S. Application No. 10/434,636 (mailed Sep. 30, 2004).
	Office Action for U.S. Application No. 10/434,636 (mailed Feb. 14, 2006).
	Office Action for U.S. Application No. 10/434,636 (mailed Jun. 1, 2007).
	Office Action for U.S. Application No. 10/235,238 (mailed Feb. 27, 2006).
	Office Action for U.S. Application No. 10/235,238 (mailed Nov. 27, 2006).
	Office Action for U.S. Application No. 10/435,406 (mailed Oct. 7, 2004).
	Office Action for U.S. Application No. 10/435,406 (mailed Feb. 13, 2006).
	Office Action for U.S. Application No. 10/435,406 (mailed Jun. 4, 2007).
	Office Action for U.S. Application No. 10/434,607 (mailed Sep. 30, 2004).
	Office Action for U.S. Application No. 10/434,607 (mailed Feb. 15, 2006).
	Office Action for U.S. Application No. 10/434,607 (mailed Jun. 1, 2007).
	Office Action for U.S. Application No. 10/305,747 (mailed Nov. 4, 2005).
	Office Action for U.S. Application No. 10/305,747 (mailed May 23, 2006).
	Office Action for U.S. Application No. 10/431,805 (mailed Sep. 30, 2004).
	Office Action for U.S. Application No. 10/431,805 (mailed Dec. 20, 2005).
	Office Action for U.S. Application No. 10/431,805 (mailed Jun. 1, 2007).
	Office Action for U.S. Application No. 10/397,953 (mailed Sep. 30, 2004).
	Office Action for U.S. Application No. 10/397,953 (mailed Feb. 15, 2006).
	Office Action for U.S. Application No. 10/397,953 (mailed Nov. 2, 2007).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	<table> <tr> <td>Attorney Docket No.</td> <td>50206/012002</td> </tr> <tr> <td>Serial No.</td> <td>10/698,572</td> </tr> <tr> <td>Applicant</td> <td>Barker et al.</td> </tr> <tr> <td>Filing Date</td> <td>October 31, 2003</td> </tr> <tr> <td>Group</td> <td>1645</td> </tr> <tr> <td>IDS Filed</td> <td>January 3, 2008</td> </tr> </table>	Attorney Docket No.	50206/012002	Serial No.	10/698,572	Applicant	Barker et al.	Filing Date	October 31, 2003	Group	1645	IDS Filed	January 3, 2008
Attorney Docket No.	50206/012002												
Serial No.	10/698,572												
Applicant	Barker et al.												
Filing Date	October 31, 2003												
Group	1645												
IDS Filed	January 3, 2008												

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Office Action for U.S. Application No. 07/655,965 (mailed Feb. 24, 1992).
	Office Action for U.S. Application No. 08/191,352 (mailed Sep. 2, 1994).
	Office Action for U.S. Application No. 08/191,352 (mailed Apr. 4, 1995).
	Office Action for U.S. Application No. 08/191,352 (mailed Dec. 22, 1995).
	Office Action for U.S. Application No. 08/191,352 (mailed Sep. 9, 1996).
	Office Action for U.S. Application No. 08/191,352 (mailed Apr. 30, 1997).
	Office Action for U.S. Patent No. 6,063,755 (mailed Sep. 9, 1996).
	Office Action for U.S. Patent No. 6,063,755 (mailed Jun. 11, 1997).
	Office Action for U.S. Patent No. 6,063,755 (mailed Aug. 19, 1998).
	Office Action for U.S. Patent No. 6,063,755 (mailed May 24, 1999).
	Office Action for U.S. Patent No. 6,316,218 (mailed Jan. 22, 1999).
	Office Action for U.S. Patent No. 6,221,840 (mailed Apr. 2, 1997).
	Office Action for U.S. Patent No. 6,221,840 (mailed Jan. 6, 1998).
	Office Action for U.S. Patent No. 6,221,840 (mailed Apr. 2, 1999).
	Office Action for U.S. Patent No. 6,221,840 (mailed Dec. 27, 1999).
	Office Action for U.S. Patent No. 6,221,840 (mailed Jul. 10, 2000).
	Office Action for U.S. Application No. 10/353,334 (mailed Feb. 8, 2007).
	Office Action for U.S. Application No. 10/353,334 (mailed Oct. 22, 2007).
	Office Action for U.S. Application No. 10/362,310 (mailed Feb. 12, 2007).
	Office Action for U.S. Patent No. 6,426,404 (mailed Jan. 20, 2000).
	Office Action for U.S. Patent No. 6,426,404 (mailed Oct. 24, 2000).
	Office Action for U.S. Patent No. 6,426,404 (mailed Jul. 17, 2001).
	Office Action for U.S. Patent No. 6,525,018 (mailed Jul. 3, 2001).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50206/012002
	Serial No.	10/698,572
	Applicant	Barker et al.
	Filing Date	October 31, 2003
	Group	1645
	IDS Filed	January 3, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Office Action for U.S. Patent No. 6,525,018 (mailed Jun. 25, 2002).
	Office Action for U.S. Application No. 10/313,642 (mailed Mar. 16, 2004).
	Office Action for U.S. Application No. 10/313,642 (mailed Dec. 22, 2004).
	Office Action for U.S. Application No. 10/313,642 (mailed Feb. 15, 2006).
	Office Action for U.S. Application No. 10/313,642 (mailed Nov. 15, 2006).
	Office Action for U.S. Application No. 10/449,456 (mailed Oct. 1, 2004).
	Office Action for U.S. Application No. 10/449,456 (mailed Feb. 15, 2006).
	Office Action for U.S. Application No. 10/449,456 (mailed Jun. 15, 2007).
	Office Action for U.S. Application No. 10/457,157 (mailed Mar. 16, 2004).
	Office Action for U.S. Application No. 10/457,157 (mailed Apr. 13, 2005).
	Office Action for U.S. Application No. 10/457,157 (mailed May 25, 2006).
	Office Action for U.S. Application No. 10/457,157 (mailed Feb. 20, 2007).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	